Trial Profile
Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after a failure to treatment with EGFR Tyrosine Kinase Inhibitors (TKI) in first line.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2016
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NAVoTRIAL 2
- Sponsors Pierre Fabre
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 28 Jul 2016 New trial record
- 07 Jun 2016 Results (n=30) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology